Welcome to our dedicated page for Protagenic Therapeutics SEC filings (Ticker: PTIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a pre-revenue biotech filing can feel like reading medical Latin. Protagenic Therapeutics’ 10-K alone packs pages of trial protocols, peptide chemistry notes and burn-rate math investors must decode before judging cash runway or dilution odds. If you have ever wondered, “Where do I find Protagenic Therapeutics SEC filings explained simply?” this page turns hours of detective work into minutes.
StockTitan’s AI reads every 10-K annual report, 10-Q quarterly earnings report and 8-K material event the moment Protagenic submits them to EDGAR. It then surfaces plain-English answers to the questions professionals actually ask: How far is PT00114 on its Phase I timeline? What do the latest “going-concern” notes imply? Our engine also flags Protagenic Therapeutics insider trading Form 4 transactions seconds after executives file, so you can track real-time buying or selling without refreshing EDGAR all day.
Need granular insight? Open the filing and let our summary module highlight drug-development milestones, cash balances and key risk-factor changes. Compare peptide pipeline spend across quarters with side-by-side 10-Q analytics. Receive alerts the moment a Protagenic Therapeutics proxy statement executive compensation emerges or when an 8-K material events explained report announces trial data.
Whether you’re monitoring Protagenic Therapeutics earnings report filing analysis, following Protagenic Therapeutics Form 4 insider transactions real-time, or simply understanding Protagenic Therapeutics SEC documents with AI, every disclosure is indexed, summarized and searchable in one place. Make informed decisions faster—no doctorate in biochemistry required.
Protagenic Therapeutics (PTIX) filed a Form 12b-25, notifying a late filing of its Form 10-Q for the period ended September 30, 2025. The company states the report could not be completed without unreasonable effort or expense and expects to file within the five-day extension permitted by Rule 12b-25.
The notice is signed by CFO Alexander K. Arrow, MD, and lists a company contact for inquiries.
Protagenic Therapeutics (PTIX) reported a board change: director Jennifer Chao resigned, effective November 3, 2025. The company stated there were no disagreements between Ms. Chao and the company. This is a routine governance update disclosed under a change in directors or certain officers.
Protagenic Therapeutics (PTIX) filed a Verified Complaint in the Delaware Court of Chancery on October 28, 2025. The filing seeks rescission of the Share Exchange Agreement dated May 15, 2025 under which PTIX acquired Phytanix Bio, Inc., or, alternatively, damages and an order compelling delivery of audited financial statements required by that agreement.
The publicly filed version of the complaint is included as Exhibit 99.1. This action centers on the terms and deliverables tied to the Phytanix transaction.
Protagenic Therapeutics (PTIX) launched an at‑the‑market offering of up to $1,750,000 in common stock under its existing sales agreement with B. Riley Securities. Shares may be sold from time to time on Nasdaq as defined by Rule 415, with the Sales Agent acting as agent or principal and earning a 3.0% commission on gross proceeds. There is no escrow arrangement.
The company indicates public float of approximately $7,911,378 based on 1,927,898 non‑affiliate shares at $4.51 as of August 25, 2025, and notes it has sold $850,715 of securities in the prior 12 months under S‑3 Instruction I.B.6, which caps sales at one‑third of public float while it remains below $75 million. Net proceeds are intended primarily to acquire potential royalty and milestone revenue streams, and for working capital and general corporate purposes.
For illustration, if 585,284 shares were sold at $2.99, the company estimates immediate dilution of $3.915 per share to new investors.
Protagenic Therapeutics (PTIX): Barrett Evans filed a Form 3 initial statement of beneficial ownership effective 05/15/2025. He is identified as a Director, 10% Owner, and ex CEO.
- Common Stock: 16,233 shares, indirect via EMC2 Capital LLC.
- Preferred Series C: 787 shares, indirect via EMC2 Capital LLC.
- Preferred Series C‑1: 131,034 shares, indirect via EMC2 Capital LLC.
- Preferred Series D: 1,000 shares direct; 4,498 shares indirect via EMC2 Capital LLC; 1,000 shares indirect via Mammoth Crest Capital LLC.
The filing notes Mr. Evans was the CEO and is a Director of PTIX.
FAQ
What is the current stock price of Protagenic Therapeutics (PTIX)?
What is the market cap of Protagenic Therapeutics (PTIX)?
